Director of New Technology Development, Bend Research Inc., USA
Michael Morgen is Director of New Technology Development at Bend Research Inc., where he has worked since 2003, focusing on formulation development and novel drug delivery technologies. He earned his Ph.D. in physical chemistry from the University of California Berkeley and has more than 15 years of experience in the development and evaluation of materials and pharmaceutical formulations for oral and non-oral delivery.
In recent years a broad range of nanotechnologies have been investigated for addressing a variety of drug delivery challenges. It has been shown by many investigators in the field that nanosized structures often possess a number of unique attributes that can be enabling for various drug delivery applications. Amorphous drug-polymer nanoparticles are one general class of nanostructured materials that have shown great flexibility and promise for such applications, including oral bioavailability enhancement and PK modification, local and systemic targeting and improved retention. Advantages of such nanoparticles can include tunabilityin the particles size, surface charge, drug loading and activity,as well as drug release rate usingeither covalent or noncovalent incorporation. In this talk, we will discuss manufacturing and physicochemical characterization methods, as well asin vitro and in vivo performance for a range of drug-polymer nanoparticles incorporating small molecule actives. Case studies will be presented that exemplify the rational choice of polymeric materials, drug incorporation method and drug loading, based on the requirements of the particular application. Examples will include applications in oral delivery, topical dermal delivery to the follicles, topical ocular delivery and formulations for increased drug retention in the joints.